the ADME Tox specialists
welcome to cyprotex

Investor News

April 1, 2003 - Preliminary Results for 14 month period ended 31 December 2002

Cyprotex PLC, a drug discovery technology and information company, today reports its preliminary results for the 14 months to 31 December 2002.

revenue for the 14 months to 31 December 2002 was £647,770 against £98,614 for the preceding 7 months to 31 October 2001
losses for the period were £3,357,182 against £386,752 for the preceding 7 months to 31 October 2001
expenditure reflects investments made to develop the business
12 deals signed including contracts with AstraZeneca, Astex Technology and Roche
moved to a customised laboratory and office facility in the UK delivering high throughput automated screening and in silico technology
Commenting on the results, John Nicholson, Chief Operating Officer of Cyprotex PLC, said:

"In common with other companies providing products to the life sciences sector, Cyprotex has faced a tough and challenging environment in its first trading period as a public company. However, the Group has continued to focus on the development and effective delivery of its core technologies whilst highlighting to the market the technical and cost benefits of Cyprotex's products. The Board is encouraged by the level of interest in its products from major pharmaceutical and international biotech companies."

Download Cyprotex Preliminary Results Including Financial Reports

For further information, please contact:
Cyprotex PLC

John Nicholson, Chief Operating Officer
Tel: +44 (0) 1625 505 100

Media enquiries:

Henry Harrison-Topham / Heather Salmond
Tel: +44 (0) 20 7444 4140

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

This website was last updated
on 16th April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.